Vantia Ltd.
- Country
- π¬π§United Kingdom
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.vantia.com
Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 432
- Registration Number
- NCT02637960
- Locations
- πΊπΈ
Vantia Investigative Center, Richmond, Virginia, United States
A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 43
- Registration Number
- NCT02537288
- Locations
- π©πͺ
PAREXEL Early Phase Clinical Unit Berlin, Berlin, Germany
Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 29
- Registration Number
- NCT02440841
- Locations
- π©πͺ
PAREXEL Early Phase Clinical Unit Berlin, Berlin, Germany
Dose Range Finding Study of Fedovapagon in Men With Nocturia
- Conditions
- Nocturia
- Interventions
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 358
- Registration Number
- NCT01656239
- Locations
- πΊπΈ
Vantia Investigative Center, Middleton, Wisconsin, United States
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)
- First Posted Date
- 2011-04-07
- Last Posted Date
- 2011-08-02
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT01330927
- Locations
- π©πͺ
Early Phase Clinical Unit, PAREXEL International GmbH, Berlin, Germany
VA106483 Dose Response in Females
- First Posted Date
- 2010-07-28
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 21
- Registration Number
- NCT01171391
- Locations
- πΊπΈ
Quintiles Phase I Services, Overland Park, Kansas, United States
Efficacy Study of VA106483 in Males With Nocturia.
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 152
- Registration Number
- NCT01038843
- Locations
- πΊπΈ
Grove Hill Clinical Research, New Britian, Connecticut, United States
πΊπΈGenova Clinical Research, Tucson, Arizona, United States
πΊπΈDiscovery Clinical Trials, Celebration, Florida, United States
VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept
- Conditions
- Primary Dysmenorrhea
- Interventions
- Drug: VA111913 TS and placebo
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 146
- Registration Number
- NCT00963053
- Locations
- πΊπΈ
Pivotal Research Centers, Peoria, Arizona, United States
π¬π§Bio-Kinetic Europe Limited, Belfast, United Kingdom
πΊπΈPremier Research Group, Austin, Texas, United States
VA106483 Dose Response Study in Elderly Males
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT00922740
- Locations
- πΊπΈ
Quintiles Phase I Services, Overland Park, Kansas, United States
Efficacy and Safety of VA106483 in Elderly Males
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 27
- Registration Number
- NCT00879138
- Locations
- π¬π§
Veeda Clinical Research, Plymouth, United Kingdom